Indeed, according to this model, it appears that FGFR3[1] is founded in a negative cross-talk from FGFR3 to EGFR, thus indirectly inhibiting the growth factor receptor EGFR, which is also a documented target in cancer therapies. This evidence concerns the gene FGFR3 and cancer.